Drug Profile
Vorinostat - Merck & Co
Alternative Names: L-001079038; MK 0683; SAHA; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; ZolinzaLatest Information Update: 15 Apr 2019
Price :
$50
*
At a glance
- Originator Columbia University; Memorial Sloan-Kettering Cancer Center
- Developer Banyu; Bayer; Columbia University; Dana-Farber Cancer Institute; Fred Hutchinson Cancer Research Center; Groupe Francophone des Myelodysplasies; H. Lee Moffitt Cancer Center and Research Institute; Indiana University; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Center for Tumor Diseases; Roswell Park Cancer Institute; Stanford University; Takeda; University Hospital Heidelberg; University of North Carolina at Chapel Hill; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Hydroxamic acids; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cutaneous T-cell lymphoma
- Phase II Acute myeloid leukaemia; B-cell lymphoma; Breast cancer; Glioma; HIV-1 infections; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
- Phase I/II Leukaemia; Lymphoma; Solid tumours
- Phase I Glioblastoma; Gliosarcoma
- No development reported Brain metastases; Colorectal cancer; Hodgkin's disease
- Discontinued Gynaecological cancer; Mesothelioma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Sickle cell anaemia
Most Recent Events
- 09 Apr 2019 Merck & Co and the Peter Doherty Institute for Infection and Immunity terminates the phase I/II DIVA trial in HIV-1 infections in Australia due to greater risk was involved in evaluation of the hypothesis in the patients than originally anticipated (NCT03198559)
- 08 Feb 2019 Merck & Co completes a phase II trial in B-cell lymphoma in South-East Asia (PO) (NCT00875056)
- 11 Jul 2018 University of North Carolina and National Institute of Allergy and Infectious Diseases terminates the pilot phase I VORVAX trial for HIV-1 infections in USA (PO) (NCT02707900)